Strikingly, in many human glioma samples where the genetic background of CNrasGEF was normal but its protein levels were low, NEDD4-1 was highly expressed, suggesting that aberrant up-regulation of NEDD4-1 might post-translationally modify CNrasGEF in cancers. The gene discussed is RAPGEF2; the disease is central nervous system cancer.